Implementing evidence‐based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024
Cancer · 2025
DOI: 10.1002/cncr.35612 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Alan H Bryce und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Therapeutics Research, City of Hope Phoenix, Phoenix, Arizona, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high‐level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day‐to‐day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US‐focused expert clinical decision‐making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration‐sensitive prostate cancer; poly [ADP‐ribose] polymerase inhibitors; prostate‐specific membrane antigen radioligand therapy; and metastatic, castration‐resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology and Therapeutics Research, City of Hope Phoenix, Phoenix, Arizona, USA.
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
- Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, Illinois, USA.
- Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
- Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA.
ORCID-Profile: Alan H Bryce, Andrew J Armstrong, Tanya Barauskas Dorff, Michael J Morris, Daniel E Spratt, Scott T Tagawa, Tian Zhang
Förderung
- NCI NIH HHS
- NCATS NIH HHS
Zitieren
APA
Bryce, A. H., Agarwal, N., Beltran, H., Hussain, M. H., Sartor, O., Shore, N., Antonarakis, E. S., Armstrong, A. J., Calais, J., Carducci, M. A., Dorff, T. B., Efstathiou, J. A., Gleave, M., Gomella, L. G., Higano, C., Hope, T. A., Iagaru, A., Morgans, A. K., Morris, D. S., …, & Crawford, E. D. (2025). Implementing evidence‐based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024. Cancer. https://doi.org/10.1002/cncr.35612
Vancouver
Bryce AH, Agarwal N, Beltran H, Hussain MH, Sartor O, Shore N, et al. Implementing evidence‐based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024. Cancer. 2025. doi:10.1002/cncr.35612
BibTeX
@article{Bryce2025,
author = {Bryce, Alan H and Agarwal, Neeraj and Beltran, Himisha and Hussain, Maha H and Sartor, Oliver and Shore, Neal and Antonarakis, Emmanuel S and Armstrong, Andrew J and Calais, Jeremie and Carducci, Michael A and Dorff, Tanya Barauskas and Efstathiou, Jason A and Gleave, Martin and Gomella, Leonard G and Higano, Celestia and Hope, Thomas A and Iagaru, Andrei and Morgans, Alicia K and Morris, David S and Morris, Michael J and Petrylak, Daniel P and Reiter, Robert E and Rettig, Matthew B and Ryan, Charles J and Sellinger, Scott B and Spratt, Daniel E and Srinivas, Sandy and Tagawa, Scott T and Taplin, Mary-Ellen and Yu, Evan Y and Zhang, Tian and McKay, Rana R and Koo, Phillip J and Crawford, E David},
title = {Implementing evidence‐based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35612}
}
EUVIMED